Sugi Predict

Sugi Predict / Compounds / SCHEMBL2485504

SCHEMBL2485504

SCHEMBL2485504

OCCOc1cccc2cccnc12

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.66
▸ RAB9A P51151 5/20 0.66
▸ LMNA P02545 4/20 0.64
▸ SMN1; SMN2 Q16637 2/20 0.64
▸ NPC1 O15118 4/20 0.62
▸ KDM4E B2RXH2 5/20 0.60
▸ MEN1 O00255 3/20 0.60
▸ KMT2A Q03164 3/20 0.60
▸ GAA P10253 2/20 0.60
▸ CYP1A2 P05177 1/20 0.59
▸ CYP3A4 P08684 1/20 0.59
▸ CYP2C9 P11712 1/20 0.59
▸ MAPK1 P28482 1/20 0.59
▸ CYP2C19 P33261 1/20 0.59
▸ POLB P06746 2/20 0.57
▸ ALDH1A1 P00352 1/20 0.56
▸ NPSR1 Q6W5P4 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL595019 0.91 RAB9A (0.65) MAPTRAB9ALMNASMN1; SMN2NPC1
SCHEMBL27858514 0.90 KDM4E (0.69) MAPTRAB9ALMNASMN1; SMN2NPC1
SCHEMBL4947880 0.90 KDM4E (0.69) MAPTRAB9ALMNASMN1; SMN2NPC1
SCHEMBL2487839 0.90 RAB9A (0.63) MAPTRAB9ALMNASMN1; SMN2NPC1
SCHEMBL535379 0.88 RAB9A (0.61) MAPTRAB9ALMNASMN1; SMN2NPC1
SCHEMBL6031547 0.84 KDM4E (0.79) MAPTRAB9ALMNASMN1; SMN2NPC1
SCHEMBL29357142 0.84 KDM4E (0.79) MAPTRAB9ALMNASMN1; SMN2NPC1
Tetraethylene Glycol SCHEMBL6031544 0.83 KDM4E (0.57) MAPTRAB9ALMNASMN1; SMN2NPC1
SCHEMBL10460812 0.82 RAB9A (0.71) MAPTRAB9ALMNASMN1; SMN2NPC1
SCHEMBL9397239 0.82 RAB9A (0.67) MAPTRAB9ALMNASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062045-B2 Triazolopyridine compounds NOVARTIS AG (CH) 2015-06-23 — — US claimed
EP-2755976-A1 6 - SUBSTITUTED 3 - (QUINOLIN- 6 - YLTHIO) - [1,2,4]TRIAZOLO [4, 3 -A]PYRADINES AS TYROSINE KINASE Novartis AG (CH) 2014-07-23 — — EP claimed
US-20130245002-A1 Triazolopyridine Compounds NOVARTIS AG (CH) 2013-09-19 — — US claimed
US-8507676-B2 Heterocyclic oxime compounds NOVARTIS AG (CH) 2013-08-13 — — US claimed
US-8410264-B2 Heterocyclic oxime compounds NOVARTIS AG (CH) 2013-04-02 — — US claimed
WO-2013038362-A1 6 - SUBSTITUTED 3 - (QUINOLIN- 6 - YLTHIO) - [1,2,4] TRIAZOLO [4, 3 -A] PYRADINES AS TYROSINE KINASE NOVARTIS AG (CH) 2013-03-21 — — WO claimed
US-20120302570-A1 HETEROCYCLIC OXIME COMPOUNDS NOVARTIS AG (CH) 2012-11-29 — — US claimed
US-20110065708-A1 HETEROCYCLIC OXIME COMPOUNDS NOVARTIS AG (CH) 2011-03-17 — — US claimed
CN-1177812-C Process for preparing O-phenoxyalkylhydroxylamine or O-phenoxyalkyloxime isomer mixtures �����ɷ� 2004-12-01 — — CN claimed
EP-0788475-B1 PROCESS FOR PRODUCING ISOMER MIXTURES FROM O-PHENOXYALKYLHYDROXYL AMINES OR O-PHENOXYALKYLOXIMES BASF AG (DE) 1999-10-20 — — EP claimed
EP-0649425-B1 PYRIDINO-, PYRROLIDINO- AND AZEPINO-SUBSTITUTED OXIMES USEFUL AS ANTI-ATHEROSCLEROSIS AND ANTI-HYPERCHOLESTEROLEMIC AGENTS UPJOHN CO (US) 1999-03-10 — — EP claimed
US-5739402-A Process for the preparation of mixtures of isomers of O-phenoxy-alkylhydroxylamines or O-phenoxyalkyloximes BASF AKTIENGESELLSCHAFT (DE) 1998-04-14 — — US claimed
CN-1150418-A Process for producing isomer mixtures from 0-phenoxyalkylhydroxyl amines or 0-phenoxyalkyloximes BASF AG (DE) 1997-05-21 — — CN claimed
EP-0649425-A1 PYRIDINO-, PYRROLIDINO- AND AZEPINO-SUBSTITUTED OXIMES USEFUL AS ANTI-ATHEROSCLEROSIS AND ANTI-HYPERCHOLESTEROLEMIC AGENTS PHARMACIA & UPJOHN COMPANY (US) 1995-04-26 — — EP claimed
CN-1100414-A Preparation of pharmaceutical compound containing novel derivative of leukol SMITHKLINE BECKMAN INTERCREDIT (NL) 1995-03-22 — — CN claimed
CN-1027368-C Process for preparing substituted quinoline derivatives SMITHKLINE BECKMAN INTERCREDIT (NL) 1995-01-11 — — CN claimed
WO-1993025553-A1 PYRIDINO-, PYRROLIDINO- AND AZEPINO-SUBSTITUTED OXIMES USEFUL AS ANTI-ATHEROSCLEROSIS AND ANTI-HYPERCHOLESTEROLEMIC AGENTS THE UPJOHN COMPANY (US) 1993-12-23 — — WO claimed
CN-1035501-A PROCESS FOR PREPARING SUBSTITUTED QUINOLINE DERIVATIVES SMITHKLINE BECKMAN INTERCREDIT (NL) 1989-09-13 — — CN claimed
US-20240051954-A1 PYRROLO[3,2-B]PYRIDINE DERIVATIVES USEFUL IN TREATING CONDITIONS ASSOCIATED WITH CGAS NOVARTIS PHARMA AG (CH) 2024-02-15 — — US disclosed
US-4081551-A OXIME ETHERS HAVING ANTI-DEPRESSIVE ACTIVITY U.S. PHILIPS CORPORATION (US) 1978-03-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240051954-A1 PYRROLO[3,2-B]PYRIDINE DERIVATIVES USEFUL IN TREATING CONDITIONS ASSOCIATED WITH CGAS CGAS, CYP11B2, GMPS MAPT 674/4885RAB9A 2195/4885LMNA 2858/4885
US-20130245002-A1 Triazolopyridine Compounds FLT3, RET, MET MAPT 1866/4885RAB9A 2684/4885LMNA 3798/4885
US-20110065708-A1 HETEROCYCLIC OXIME COMPOUNDS MET, ERBB2, TIE1 MAPT 2873/4885RAB9A 3906/4885LMNA 3896/4885
US-20120302570-A1 HETEROCYCLIC OXIME COMPOUNDS MET, ERBB2, TIE1 MAPT 2873/4885RAB9A 3906/4885LMNA 3896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.